Skip to content
Search

Latest Stories

Antibiotic-resistant infections exceed pre-pandemic levels – warns UKHSA

Penicillins were the most frequently prescribed antibiotics in both primary and secondary care; antibiotic resistance UK
A container filled with blister-packaged capsules (gettyimages)

Penicillins were the most frequently prescribed antibiotic group in both primary and secondary care

The UK recorded an estimated 66,730 serious antibiotic-resistant infections in 2023, surpassing the pre-pandemic figure of 62,314 in 2019, a new report from the UK Health Security Agency (UKHSA) has revealed.

Antibiotic resistant bacteria are less likely to respond to treatment and can cause serious complications, including bloodstream infections, sepsis and hospitalisation.


The national surveillance data published by the UKHSA showed that E. coli – a common cause of urinary tract infections, diarrhoea, vomiting and fever, accounted for 65 per cent of antibiotic-resistant bloodstream infections in the last five years.

The English Surveillance of Antibiotic Prescribing and Utilisation Report (ESPAUR) highlighted a stark disparity in infection rates.

People in the most deprived communities were 42.6 per cent more likely to experience an antibiotic-resistant infection in 2023 compared to those in the least deprived areas, a significant rise from 29.4 per cent in 2019.

Overall, resistant infection rates in the most deprived areas of England increased by 9.5 per cent between 2019 and 2023.

Antibiotic use rose by 2.4 per cent in 2023 compared to 2022, with prescribing levels returning to those last seen in 2019. Penicillins were the most commonly prescribed antibiotics in both primary and secondary care.

Professor Dame Jenny Harries, CEO of UKHSA, warned of the increasing risks posed by antibiotic resistance.

She said: “Increasingly the first antibiotics that patients receive aren’t effective at tackling their infections. That’s not just an inconvenience – it means they are at greater risk of developing a severe infection and sepsis.

“Our declining ability to treat and prevent infections is having an increasing impact, particularly on our poorest communities.”

While UKHSA continues to collaborate on innovative ways to combat antibiotic resistance, Professor Harries urged the public to take proactive steps:

  • Take up the vaccinations that you are eligible for to help stop infections.
  • Only take antibiotics when prescribed by a healthcare professional.
  • Do not save antibiotics for later or share them with friends and family.

“This isn’t just for your own health - it’s about protecting everyone in our communities and future generations,” she added.

 

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less